Trial · NCT07072221
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
NCT07072221, Not applicable, Recruiting, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients. Trials, record NCT07072221. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07072221
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
- NCT number
- NCT07072221
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- BCL regimen, Cohort 1 (ASCT-eligible), Cohort 2 (ASCT--ineligible)
- First posted
- 2025-07-18
- Last updated
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate(CRR) | At the end of 4 cycles of BCL regimen (each cycle is 28 days) | The rate of patients who achieved CR after 4 cycles of bendamustine combined with chidamide and lenalidomide therapy (BCL regimen). |
| Secondary | Main adverse events | From enrollment to 1 month after the end of last patient's treatment | The safety and tolerability of the BCL regimen measured by the major adverse events. |
| Secondary | Overall response rate(ORR) | At the end of 4 cycles of BCL regimen (each cycle is 28 days) | The rate of patients who achieved CR or PR after treatment of 4 cycles of BCL regimen |
| Secondary | 2-year Overall survival(OS) | From enrollment to 2 years after the last patient's treatment | OS will be assessed from the start of the BCL treatment to the date of death or end of follow-up. |
| Secondary | 2-year progression-free survival(PFS) | From enrollment to 2 years after the last patient's treatment | PFS will be assessed from the start of the BCL treatment to the date of progression, relapse, death or end of follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07072221
GET https://conductscience.org/api/trials/v1/NCT07072221/registered